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Protein O-mannosylation 
deficiency increases LprG-
associated lipoarabinomannan 
release by Mycobacterium 
tuberculosis and enhances the 
TLR2-associated inflammatory 
response
Henar Alonso, Julien Parra, Wladimir Malaga, Delphine Payros, Chia-Fang Liu, Céline 
Berrone, Camille Robert, Etienne Meunier, Odile Burlet-Schiltz, Michel Rivière & Christophe 
Guilhot
Protein O-mannosylation is crucial for the biology of Mycobacterium tuberculosis but the key 
mannosylated protein(s) involved and its(their) underlying function(s) remain unknown. Here, we 
demonstrated that the M. tuberculosis mutant (Δpmt) deficient for protein O-mannosylation exhibits 
enhanced release of lipoarabinomannan (LAM) in a complex with LprG, a lipoprotein required for LAM 
translocation to the cell surface. We determined that LprG is O-mannosylated at a unique threonine 
position by mass spectrometry analyses of the purified protein. However, although replacement of this 
amino acid by an alanine residue completely abolished LprG O-mannosylation, the increased release of 
the LAM/LprG complex was preserved. We found that the increased secretion of this complex is due to 
enhanced LAM production in the Δpmt M. tuberculosis and M. smegmatis mutants relative to their wild-
type counterparts. This abnormal release of LAM/LprG has functional consequences on the induction 
of inflammatory responses and provides a possible explanation for the reduced virulence of the M. 
tuberculosis Δpmt mutant.
Glycosylation is one of the most common post-translational modifications of proteins that considerably affects 
protein properties/functions and biological activities in eukaryotes. Until recently, protein glycosylation was 
thought to occur only rarely in prokaryotes with limited impact on their biology1. However, the analysis of protein 
reactivity with the lectin Concanavalin A and the development of mass spectrometry (MS) for protein analysis 
have revealed that several proteins in actinomycetes are O-mannosylated, especially in the human major path-
ogen, Mycobacterium tuberculosis. The first identified glycoproteins were the secreted antigens PstS1 (38 kDa), 
the alanine-proline rich Apa protein (45–47 kDa) and the lipoprotein LpqH (19 kDa)2–5. These results garnered 
immediate widespread attention because this post-translational modification may play an important role in the 
biology of M. tuberculosis and the host/pathogen interaction. Indeed, M. tuberculosis is the causative agent of 
human tuberculosis (TB), a disease which still remains a major public health concern with 10.4 million new cases 
and 1.8 million deaths in 20156. A better understanding of the strategies used by this pathogen to circumvent the 
host immune defense, and thus to persist and to cause disease, may reveal weak spots in the TB bacilli that can be 
exploited to develop innovative approaches to control this important pathogen and the associated disease.
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O-mannosylated proteins purified from mycobacteria bind to host innate-immune receptors, such as lung 
surfactant protein A, DC-SIGN (dendritic-cell-specific intercellular molecule-3-grabbing non-integrin), and the 
mannose receptor and contribute to phagocyte invasion7–9. In addition, T cell antigenicity of secreted M. tuber-
culosis glycoproteins is modulated by the pattern of O-mannosylation. The best documented example is the Apa 
antigen, which contains up to nine mannose residues when purified from M. tuberculosis or the model mycobac-
terial strain Mycobacterium smegmatis, but no sugar residue when expressed in, and purified from, Escherichia 
coli10, 11. The glycosylated forms of Apa induce strong delayed-type hypersensitivity reactions (DTH) in vivo and 
exhibit a high capacity to stimulate T lymphocyte responses of guinea pigs immunized with BCG. In contrast, 
non-glycosylated Apa, obtained either following deglycosylation of the native form from M. tuberculosis or puri-
fied from E. coli, is more than 10-fold less potent in inducing these responses10, 11. Similar results have been 
obtained in mice and humans showing that O-mannosylation of Apa enhances its T cell antigenicity12. However, 
glycosylation of this antigen is dispensable for the induction of a protective immune response in mice12.
The key finding demonstrating the major role played by O-mannosylation in the biology of TB bacilli came 
from the construction and the phenotypic characterization of a defined M. tuberculosis mutant deficient for 
this post-translational modification13. VanderVen et al.14 identified a protein, encoded by the Rv1002c gene 
in M. tuberculosis, that exhibits sequence similarities with membrane-associated protein O-mannosyl trans-
ferase from Saccharomyces cerevisiae. They demonstrated that Rv1002c (pmt) encodes an O-mannosyl trans-
ferase that catalyzes the initial step of protein glycosylation in M. tuberculosis and that this process is coupled 
to Sec-translocation14. Knock-out of Rv1002c, and its ortholog Msmeg_5447, in M. tuberculosis and M. smegma-
tis respectively demonstrated that these genes are dispensable for in vitro mycobacterial growth, in contrast to 
eukaryotes where protein O-mannosylation is required for viability13. Mass-spectrometry (MS) analyses showed 
that the mutant strains were indeed deficient in protein O-mannosylation consistent with the hypothesis that 
Rv1002c and MSMEG_5447 have no paralogs in M. tuberculosis and M. smegmatis respectively. The M. tubercu-
losis ΔRv1002c::km (Δpmt) mutant displayed several phenotypes in vitro and in vivo demonstrating that protein 
O-mannosylation is a major post-translational modification for the biology of this pathogen. First, the ability of 
the Δpmt mutant to form colonies on solid medium was profoundly impaired and it exhibited delayed growth 
in liquid medium containing dextrose as the sole carbon source. Second, this mutant was strongly attenuated in 
several cellular and animal infection models: its growth in mouse alveolar macrophages or primary human blood 
monocyte-derived macrophages and its capacity to kill immunocompromised mice were severely impaired13. 
These results established Rv1002c as a membrane-associated protein O-mannosyl transferase of crucial impor-
tance for the biology of M. tuberculosis and especially for its interaction with the host. However, these studies 
did not identify the Rv1002c-target proteins responsible for the in vitro growth defect and attenuated phenotype 
when not glycosylated.
Two main strategies have been used to identify glycosylated proteins in M. tuberculosis. Zamorano et al.15 
performed glycoproteins enrichment using the lectin Concanavalin A, followed by 2D gel electrophoresis and 
conventional mass spectrometry analysis of the individual spots. They identified 41 proteins, but did not provide 
direct evidence that they were indeed glycosylated. More recently, advances in MS technologies have allowed 
the development of analytical approaches to directly search for glycopeptides in complex protein extracts. For 
example, Smith et al.16 used liquid chromatography (LC) coupled to tandem MS analyses to identify 14 glycopep-
tides, and to localize their glycosylsation sites, in M. tuberculosis culture filtrate corresponding to 13 glycosylated 
proteins. These results largely extended the repertoire of M. tuberculosis glycoproteins but did not address the 
question of the impact of this post-translational modification on the functions of these proteins.
Here, we aimed to address this question and to examine how the O-mannosylation of M. tuberculosis proteins 
may contribute to host/pathogen interactions. We identified the lipoprotein, LprG, as a new O-mannosylated 
protein and characterized its glycosylation site. We demonstrated that the lack of protein O-mannosylation is 
associated with increased production of lipoarabinomannnan (LAM), a critical mycobacterial virulence factor17, 
and increased release of this lypoglycan complexed with LprG. We found that this perturbation is associated with 
enhanced stimulation of Toll-Like Receptor 2 (TLR2), a key host receptor to control M. tuberculosis infection18, 
and a stronger induction of inflammatory responses by infected macrophages.
Results
Phenotypes of M. tuberculosis mutants deficient in selected mannoprotein production. We 
applied the recently developed glycopeptidomics approach13 for the analysis of the M. tuberculosis secretome to 
further enrich the mannoprotein repertoire of M. tuberculosis. The combination of high efficiency SDS-PAGE 
based shotgun MS proteomics and automated post-analytical data mining led to the unambiguous characteri-
zation of several tryptic glycopeptides allowing the identification of the parent glycoproteins. Five of them, i.e. 
Rv0175, Rv0315, Rv0838 (LpqR), Rv1411c (LprG) and Rv3491, were then selected on the basis of the confidence 
of their glycopeptide identification (Supplementary Figure S1), their novelty with regards to previously charac-
terized O-mannosylated M. tuberculosis proteins and their putative role in pathogenicity (Table 1). We reasoned 
that if O-mannosylation affects the function of a protein in a defined condition, then a knock-out mutation of the 
corresponding gene should also affect the phenotype in the same condition. Therefore, we individually disrupted 
each of the five target genes in the M. tuberculosis reference strain H37Rv and introduced a kanamycin resist-
ant marker (km) together with an oligonucleotide specific tag by homologous recombination (Supplementary 
Figure S2). None of the mutants exhibited growth defects in standard ADC-enriched 7H9 liquid medium 
(Fig. 1A). However, the colony forming capacity of ΔlprG was impaired on 7H11 supplemented with OADC 
(Fig. 1B). This observation is similar to the strong growth defect on solid medium described for the H37Rv 
Δpmt13, although the phenotype was not as severe for the ΔlprG strain. None of the other mutants displayed 
growth alterations on solid medium (Supplementary Figure S3). Complementation of the ΔlprG mutant with the 
lprG-Rv1410c operon restored the capacity to form colonies on agar plates (Fig. 1B and Supplementary Figure S3).
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One of the more striking feature of the M. tuberculosis Δpmt mutant is its strong attenuation in cellular and 
animal infection models. We therefore evaluated the in vivo growth of the five mutants in BALB/c mice. We 
monitored the in vivo replication using qPCR in a competition experiment as described by Blumenthal et al.,19 
to avoid any mis-interpretation associated with the altered capacity to form colonies on solid medium. Each 
mutant and the wild type strain was tagged using a specific oligonucleotide sequence. The tagged strains were 
grown independently in liquid medium and an inoculum was prepared by mixing similar quantities of each 
clone (Supplementary Figure S4). Mice were then infected intranasally using 6 × 102 cfu of the mixed popu-
lation (Supplementary Figure S4). At each time point, the bacterial load in lung and spleen was quantified by 
plating serial dilution of lung and spleen homogenates. As expected, we observed a five-log increase during the 
four-week-infection period (Figure S4). In parallel, the organ homogenates were used to grow a short-term cul-
ture used to extract total DNA and to evaluate the relative quantity of each strain by qPCR. The relative quantity 
of ΔRv0175 and ΔlprG was similar to that of the other mutants and wild type control in the inoculum, but their 
proportional representation decreased substantially during the infection time-course (Fig. 2C and Supplementary 
Figure S4). Conversely, the quantity of the other strains increased. These results show that the ΔRv0175 and 
ΔlprG mutants were attenuated in this competition experiment.
Based on these results, we focused our study on the LprG protein. Indeed, the phenotype of the H37Rv ΔlprG 
strain exhibited striking similarities with those of the Δpmt mutant, suggesting that the latter may be due, at least 
in part, to lack of LprG mannosylation and subsequent alteration of LprG functions.
Impact of O-mannosylation on LprG-associated localization of LAM. LprG belongs to the M. 
tuberculosis lipoprotein family and appears to act in concert with the efflux pump P55, encoded by the gene 
Rv1410c, which forms an operon together with lprG on the M. tuberculosis chromosome20. Several biological roles 
of LprG were recently described which provide tractable activities on which the impact of O-mannosylation can 
be evaluated. LprG together with P55 provides protection against toxic compounds such as ethidium bromide 
and malachite green21, 22. LprG is able to bind to various glycolipids such as lipoarabinomannan (LAM), lipoman-
nan and phosphatidylinositol mannoside (three groups of molecules which share a similar core structure)23 and 
triglycerides24. LprG mutants exhibit impaired surface exposition of LAM25, 26, suggesting that the biological role 
of this lipoprotein is to transfer LAM from the plasma membrane to the bacterial cell surface.
We examined whether the lack of O-mannosylation alters one or more functions of LprG. We first evaluated 
the presence of LAM at the surface of the WT H37Rv strain and the Δpmt and ΔlprG isogenic mutants using 
FACS (Fig. 2A). As expected, disruption of lprG decreased the surface display of LAM, a phenotype reversed by 
complementation with the lprG-Rv1410c operon. However, the Δpmt strain exhibited a level of LAM exposition 
similar to that of the WT strain, suggesting that the lack of LprG glycosylation does not prevent the translocation 
of LAM. We further explored the impact of glycosylation on LprG function by testing whether co-purification 
of LAM with LprG was affected in a mycobacterial strain deficient for O-mannosylation. We expressed LprG 
fused to a Hexahistidine (His)-tag in the WT H37Rv or the Δpmt isogenic mutant. We then affinity purified 
the LprG-His protein from either the culture filtrate or the bacterial cells and measured the amount of LAM 
co-purified with LprG-His by Western blot using an anti-LAM antibody. Similar amounts of LAM were associ-
ated with the LprG-His protein purified from the pellet of the Δpmt mutant and the WT strain (Fig. 2B). In sharp 
contrast, the amount of LAM associated with LprG-His recovered from the culture filtrates was much higher for 
the Δpmt mutant than for the WT strain. This suggests that the O-mannosylation defect favors the release of 
the LAM associated with LprG in the bacterial culture filtrate. We tested whether this effect was restricted to M. 
tuberculosis by expressing the LprG-His protein in M. smegmatis mutated for the MSMEG_5447 (the ortholog of 
Rv1002c) gene (MSMEG-5447::res or Δpmt mutant) or the isogenic strain complemented with Rv1002c from M. 
tuberculosis. Similar amounts of LAM were co-purified with LprG-His from the pellets of the M. smegmatis Δpmt 
mutant and the Rv1002c-complemented strain, whereas much higher LAM were associated with the protein puri-
fied from the Δpmt mutant culture supernatant, as observed in the M. tuberculosis background (Supplementary 
Figure S5).
Peptide sequence
Experimental 
Mass (Da)
Calculated 
Mass (Da) Delta (Da)
Hexose 
number
Peptide 
score
Protein 
Access # Rv gene Gene Name Protein description
required for
in-vitro 
growthd
in-vivo 
growthe
D100C*VAATaQAPDAGAMS 
ASMQK119b
2170,9 2008,9 162,1 1 121,2 O07419 Rv0175 mce1F Mce associated membrane protein − +
P39AGPTPAPAAPAAAT 
GGLLFHDEFDGPAGSVPDPSK74
3544,7 3382,6 162,1 1 28,62 O07242 Rv0315c β-1,3-glucanase precursor − +
T47TTPSGPVPPVSEAAR62 1889,9 1565,8 324,1 2 55,3 O53850 Rv0838 lpqR
D-alanyl-D-alanine 
dipeptidase − nr
V228QVTKPPVS236 1115,6 953,6 162,1 1 24,94 P9WK45 Rv1411cc lprG
Lipoarabinomannan 
carrier protein LprG − +
Q164PFSLQLIGPPPSPVQR180 b 2022,1 1860,0 162,1 1 49,06 I6XHD1 Rv3491c
Predicted secreted 
protein − nr
Table 1. Selected M. tuberculosis mannoproteins with high confidence glycopeptidomics identification. 
*Carbamidomethyl cysteine; a: Underlined italic characters figure the potential glycosylation sites predicted 
by Net-O-Glyc 3.1 server; b: also reported by Smith et al., 2014; c: also detected by ref. 15; d: according41, 42; e: 
according43, 44; nr: not reported.
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Altogether, these results suggest that the lack of O-mannosylation increased the amount of LAM released in 
the supernatant in association with LprG.
Identification of the LprG glycosylation site. We tested whether the lack of LprG O-mannosylation 
was responsible for the higher association of LAM with LprG observed with the Δpmt mutant, by targeting 
specifically the LprG glycosylation. We first further characterized the LprG mannosylation status and precisely 
determined the glycosylation site(s) by high resolution mass spectrometry (HR-MS) and top-down fragmen-
tation experiments of the intact protein. Deconvolution of the ESI-HRMS spectrum of the purified recombi-
nant LprG-His expressed in M. tuberculosis revealed two molecular species of molecular mass of 22,379 Da and 
22,541 Da (Fig. 3A and B). The 162 Da difference in mass between these two peaks is consistent with the mass of 
an hexose moiety, suggesting that these two molecular species correspond to the unmodified and monoglyco-
sylated proteoforms of a truncated form of LprG (Fig. 3A and B) missing the N-terminal pentapeptide (expected 
average mass of 22,379 Da and 22,541 Da). Top-down fragmentation of the intact protein precursors supported 
Figure 1. Contribution of selected mannoproteins to M. tuberculosis growth in vitro and in vivo. (A) Growth 
of WT M. tuberculosis and mutants in liquid medium. Mycobacterial strains were inoculated at 106cfu/ml. 
Absorbance at 600 nm was followed over time for the various cultures. (B) Growth of WT M. tuberculosis and 
mutants on 7H11 Petri plates. Serial dilutions of adjusted liquid cultures of the various mutants were spotted 
on solid medium and incubated at 37 °C. (C) Growth of tagged-WT M. tuberculosis and tagged-mutants in 
BALB/c mice. Mice (5 for each time points) were infected with 6.102 cfu of a population containing similar 
concentration of each strains. At 1, 14 or 28 days post-infection, the bacterial population was recovered from 
the lung of the infected mice and grown for 7 days in liquid medium. Total DNA was extracted and the quantity 
of each mutant evaluated by qPCR using primers specific for the tags. The amount of each mutant relative to the 
inoculum is plotted.
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Figure 2. Impact of protein O-mannosylation on LAM exposition to the bacterial cell surface and release 
of the LprG/LAM complex. (A) FACS analyses of LAM staining on the surface of the various M. tuberculosis 
strains. The bar graph values correspond to the median fluorescence value after normalization to H37Rv. Results 
are representative of two independent experiments. *P < 0.05. (B) Western-blot analyses of LAM associated 
with LprG in WT M. tuberculosis or Δpmt mutant. Similar amounts of LprG-His protein purified from the 
bacteria or culture medium were separated by SDS-PAGE. After transfer, the LAM or LprG-His molecules were 
revealed using the anti-LAM antibody CS-35 or an anti-His antibody. Blots are representative of at least three 
independent experiments.
Figure 3. MS analyses of LprG and LprG T231A glycosylation. (A) Deconvoluted ESI-HRMS spectrum of the 
purified recombinant LprG-His expressed in M. tuberculosis. (B) Peptide sequence of the molecular species 
observed in A reporting the fragment ions detected in the top-down electron transfer dissociation spectrum of 
the fragmentation of the 22,541 Da molecular mass ion precursor allowing the localization of the unique hexose 
on the T231. (C) Deconvoluted ESI-HRMS spectrum of purified recombinant LprG-His T231A expressed in 
M. smegmatis demonstrating the absence of glycosylation of the mutated protein. (D) Peptide sequence of the 
molecular species observed in C.
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these assignments and further allowed the identification of T231 as the unique glycosylation site of the glyco-
form 22,541 Da protein (Figs 3B and S6). We produced a lprG A691G point mutant (lprG*), encoding a LprG 
protein containing a T231A mutation, fused with a His-tagged coding sequence, to evaluate the impact of the 
mannosylation on the activities of the protein. This construct was expressed in the M. smegmatis Δpmt mutant 
complemented with Rv1002c and the LprG-His T231A protein was purified and analyzed by MS in a same way. 
As expected, we detected a unique molecular species with a molecular mass of 22,436 Da (Fig. 3C and D) consist-
ent with a mutated T231A form of LprG, confirming that the mutated protein was no longer O-mannosylated. 
However, although the molecular mass of this molecular species is consistent with the T231A mutation, it is 
noteworthy that it corresponds to a slightly longer truncated form of LprG starting from the upstream N terminal 
serine residue (Fig. 3C and D). This alternative sequence truncation was confirmed by top-down MS experiments 
and suggests that the absence of glycosylation may affect the proteolytic cleavage of the protein N terminus as 
previously reported5.
Impact of LprG O-mannosylation on mycobacterial growth and association with LAM. We next 
addressed whether the lack of LprG glycosylation directly affects its functions. We generated a complementation 
plasmid carrying the lprG* mutated gene in an operon with Rv1410c and transferred this construct into the 
H37Rv ΔlprG mutant. We verified whether the production of LprG T231A complements the ΔlprG mutation. 
We first evaluated their colony-forming capacity on 7H11 OADC solid medium and found no difference between 
the strains producing the wild type LprG or the LprG T231A mutated protein, indicating that the LprG T231A is 
functional (Supplementary Figure S7). We next tested whether the T231A mutation affects the capacity of LprG 
to co-purify with LAM. The LprG-His and LprG-His T231A proteins were purified either from the M. smegma-
tis Δpmt mutant or from the isogenic strain complemented with Rv1002c. Western-blot analyses revealed that 
similar amount of LAM co-purified with LprG-His and LprG-His T231A recovered from the same M. smegmatis 
background. However, the LAM signal was much higher when the proteins were purified from the supernatant of 
the Δpmt mutant than complemented M. smegmatis (Fig. 4). In contrast, the amount of LAM in the cell extracts 
was slightly higher for the complemented strain than for the Δpmt mutant suggesting that the LAM/LprG com-
plex is more efficiently retained in the cells when protein-O-mannosylation is preserved (Fig. 4).
Altogether these results establish that the enhanced capacity of LAM to co-purify with secreted LprG when 
produced in M. smegmatis Δpmt mutants is not due to LprG mannosylation but rather to an indirect effect.
Impact of protein O-mannosylation on steady state level of LAM. The higher amount of LAM 
found associated with LprG in the supernatant of the Δpmt mutants might be due to a higher steady state level 
of these compounds. We evaluated the total amount of LAM found in the M. tuberculosis WT, Δpmt and ΔlprG 
mutants and complemented strains. We prepared crude extracts from bacterial pellets or culture supernatants, 
separated the compounds by SDS-PAGE, and then performed Western blot analysis using either anti-LAM, or 
anti-hsp65 and anti-Ag85A antibodies as controls for the cell-associated or extracellular proteins, respectively 
(Fig. 5). As expected, the bacterial pellets contained similar amounts of LAM, but the culture supernatant of 
the Δpmt mutant exhibited approximately 10 fold more LAM than that of the WT cells. This phenotype was 
reverted by complementation with pmt from either M. tuberculosis or M. smegmatis (data not shown). In contrast, 
the amount of LAM was similar in both fractions for the other mutant and complemented strains, including 
the strain expressing the LprG-His T231A. This finding was not restricted to M. tuberculosis because similar 
Figure 4. Impact of LprG O-mannosylation on the release of the LprG/LAM complex in M. smegmatis. 
Similar amounts of LprG-His or LprG-His T231A purified from either culture medium or bacterial cells were 
separated by SDS-PAGE, transferred onto membranes and revealed using anti-LAM or anti-His antibodies. The 
genetic backgrounds in which the protein was produced are indicated. The upper band revealed by the anti-His 
antibody is a non-specific cross-reacting protein. The signal intensity for LAM was quantified and plotted in the 
graph below the Western blot image. This blot is representative of three independent experiments.
www.nature.com/scientificreports/
7SCIeNTIFIC REPORts | 7: 7913  | DOI:10.1038/s41598-017-08489-7
results were obtained for crude extracts from M. smegmatis WT and the Δpmt mutant (data not shown). These 
results demonstrate that the production of LAM and its release into the culture medium is enhanced in the Δpmt 
mutants, independently of the LprG mannosylation.
Protein O-mannosylation and induction of inflammatory response. LprG plays a key role in the 
cross-talk between M. tuberculosis and the host by interacting with the host receptor, TLR2, and by modulating 
the inflammatory response23, 27. This TLR2 agonist activity is strongly enhanced by LAM association with LprG23. 
The higher release of LAM/LprG complex may be associated with modification of the interaction of M. tubercu-
losis Δpmt mutant with macrophages. We first infected human monocyte-derived macrophages (hMDM) at an 
MOI of 1:1 for 1 h with the Δpmt or ΔlprG mutants, the WT control or the complemented strains and monitored 
the percentage of infected cells and the number of bacteria per cell for seven days. For this purpose, the strains 
were transformed with a plasmid expressing the fluorescent protein GFP. As we previously observed, the Δpmt 
mutant showed impaired invasion and growth in hMDM13. The ΔlprG mutant exhibited a similar defect of inva-
sion capacity (lower percentage of infected cells and lower number of bacteria/cell) after seven days of infection. 
Complementation with either the WT lprG or mutated lprG A691G in operon with Rv1410c restored full viru-
lence in this cellular model (Fig. 6A and Supplementary Figure S8). These results demonstrate that the lack of 
LprG O-mannosylation was not responsible for the attenuation observed with either the ΔlprG or Δpmt mutant.
We next evaluated whether the inflammatory response of infected cells was affected by the Δpmt muta-
tion. We used cell lines to limit the variability associated with primary cells. We infected human (THP-1) 
or mice macrophages (MHS) at MOI 1:1 for 1 h with either the wild type H37Rv, the Δpmt mutant, and the 
Rv1002c-complemented strain and assayed inflammatory (TNF-α) or anti-inflammatory (IL-10) cytokines at 
5, 24 and 48 h post-infection. We detected a significantly greater TNF-α release by MHS cells after infection 
with the Δpmt mutant than with the WT or complemented strains and a similar trend was observed in THP-1 
cells (Fig. 6B and Supplementary Figure S8). In contrast, the secretion of the anti-inflammatory cytokine IL-10 
decreased markedly in both cell types. We next addressed whether this higher inflammatory response may be due 
to greater stimulation of TLR2 using a HEK293 cell line stably transfected with human TLR2 and CD14 genes and 
an NF-κB-inducible reporter gene. We prepared crude extracts from the bacterial pellets and culture supernatants 
of Δpmt, ΔlprG mutants, and controls and incubated them with HEK-TLR2 cells. The culture supernatants from 
the Δpmt mutant activated NF-κB more than the similar extract from the WT strain (1.6-fold increase, p < 0.001) 
(Fig. 6C). In contrast, similar TLR2 activation was observed for the ΔlprG mutant and strains producing either 
the WT LprG or the non mannosylated LprG T231A (data not shown). The difference observed for the Δpmt 
sample was restricted to the culture supernatant because the crude extracts obtained from the various bacterial 
pellets gave similar NF-κB activation. These results are consistent with the higher secretion of the LprG/LAM 
complex associated with the Δpmt mutation.
We next tested the LprG-His protein purified from the culture medium or bacterial pellets from the WT M. 
tuberculosis or the Δpmt mutant for their TLR2 agonist activity (Fig. 6D). NF-κB activation was slightly higher 
for the proteins purified from the WT bacterial pellets than the Δpmt cells when equal amounts of LprG-His were 
incubated with HEK-TLR2 cells. In contrast, we measured much higher NF-κB activation with LprG-His purified 
from the supernatant of the H37Rv Δpmt mutant than from the supernatant of the WT strain (1.5-fold increase, 
Figure 5. Impact of protein O-mannosylation on LAM production. Crude extracts obtained from the 
culture medium (B) or bacterial cells (A) were separated by SDS-PAGE, transferred onto membranes, and 
analyzed using antibodies raised against LAM and either hsp65 (for cellular extracts) or Ag85A (for medium 
supernatants). The signal intensity for LAM was quantified and plotted in the graph below the western blot 
image. This blot is representative of two independent experiments.
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Figure 6. Protein O-mannosylation affects the inflammatory response of infected cells. (A) Growth of WT, 
mutants and complemented strains in hMDM. hMDM were infected at an MOI 1 for 1 h with the indicated 
strains. Data are presented as the mean +/− SD of four independent experiments performed in duplicate. 
(B) Production of TNF-α and IL-10 by MHS cells infected by WT, Δpmt and complemented strains. MHS 
cells were infected at MOI 1:1 for 1 h and TNF-α and IL-10 were evaluated after 5 h or 24 h and 24 or 48 h 
respectively. Data are representative of two independent experiments performed in triplicate. (C) NK-κB 
activation in HEK-TLR2 cells incubated with crude extracts from WT and Δpmt M. tuberculosis strains. 
Activation of NF-κB, evaluated using SEAP activity, following incubation with 500 ng/ml or 50 ng/ml of crude 
extracts recovered from either bacterial cells or culture medium from the indicated M. tuberculosis strains. PBS 
1× or PAM3CSK4 (10 ng/ml) were used as negative and positive controls respectively. Data are presented as 
the mean +/− SD of three independent experiments. (D) NF-κB activation in HEK-TLR2 cells incubated with 
LprG/LAM complex purified from bacterial cells or culture medium of WT or Δpmt M. tuberculosis strains. 
HEK-TLR2 cells were incubated with 10 ng/ml or 1 ng/ml of LprG-His and co-purified LAM. SEAP activity was 
quantified after 24 h. PBS 1× or PAM3CSK4 (10 ng/ml) were used as negative and positive controls respectively. 
Data are presented as the mean +/− SD of at least five independent experiments. *P < 0.05; **P < 0.01; 
***P < 0.001; ****P < 0.0001.
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p < 0.001 for 10ng/ml purified proteins and 3.4-fold increase, p < 0.005 for 1 ng/ml). We obtained similar results 
with LprG-His purified from either the bacterial pellet or culture supernatant from the M. smegmatis Δpmt 
mutant or the isogenic strain complemented with Rv1002c (Supplementary Figure S9). The T231A mutation, and 
as a consequence the glycosylation status of LprG, did not affect the induction of NF-κB (data not shown).
Finally, we confirmed that LprG/LAM signals primarily through TLR2 using bone marrow-derived mac-
rophages (BMDM) from WT, TLR2 −/−, or MyD88−/− mice. Incubation of WT BMDM with the LprG/LAM 
complex induced the production of TNF-α. Consistent with results obtained with HEK-TLR2 cells, we measured 
higher TNF-α release with LprG/LAM purified from culture medium from the M. smegmatis Δpmt than from 
the Rv1002c-complemented strain in WT macrophages and the opposite for samples obtained from the bacterial 
pellets. The TNF-α release was abrogated in TLR2 −/− BMDM as in macrophages deficient for MyD88, the com-
mon adaptor protein for most TLR (Supplementary Figure S10).
Altogether, these results clearly establish that the lack of protein glycosylation is associated with a greater 
induction of the TLR2-mediated inflammatory response during host-cell infection. This effect is explained, at 
least in part, by the higher release of the LAM/LprG complex.
Discussion
The molecular mechanisms explaining the various phenotypes associated with the lack of protein 
O-mannosylation in mycobacteria are unknown. In M. tuberculosis, these phenotypes include a marked defi-
ciency to form colony and severe attenuation in mouse and cellular models of infection13. Here, we demonstrated 
that the M. tuberculosis Δpmt mutant induces a stronger inflammatory response by infected phagocytes than the 
WT strain. This pro-inflammatory phenotype may be explained by higher secretion of the LAM/LprG complex 
which stimulates the TLR2 signaling pathway leading to NF-κB activation. Although LprG is O-mannosylated, 
this modification does not influence release of the LAM/LprG complex. Rather, disruption of mycobacterial pmt 
leads to a higher steady-state level of LAM and release in the supernatant of mycobacterial cultures. The addi-
tional LAM in the medium, at least in part bound to LprG, is likely the molecular basis underlying the greater 
induction of the inflammatory response through potentiation of the TLR2 agonist activity of LprG.
This conclusion is supported by several lines of evidence. First the greater inflammatory response induced 
in human and mouse macrophages by the M. tuberculosis Δpmt mutant was reproduced in a simpler system 
using either non phagocytic HEK-TLR2 cells or BMDM from WT or TLR2 −/− mice and either the mycobacte-
rial culture supernatant or the purified LprG/lipoglycan complex. Second, the T231A point mutation abolished 
LprG O-mannosylation but had no effect on NF-κB activation and accumulation of LprG/LAM complex. Finally, 
although the LprG lipoprotein was found to exhibit TLR2 agonist activity23, 27, association with mycobacterial 
lipoglycans (including LAM) strongly enhanced this activity23. However, further studies are required to deter-
mine whether this stronger induction of the TLR2 mediated response accounts for the attenuation observed 
with the M. tuberculosis Δpmt mutant in the mouse model. In the last decade, TLR2 has emerged as a major host 
receptor for host/pathogen cross talk and immune response against M. tuberculosis (for review28, 29). TLR2 signal-
ing mediates the control of M. tuberculosis through a wide range of host immune responses including macrophage 
activation, pro-inflammatory cytokine release, Th1 response and apoptosis28. Accordingly, TLR2-deficient mice 
exhibit higher susceptibility to M. tuberculosis infection than WT mice18, 30. However, M. tuberculosis may also use 
TLR2 signaling to escape the host immune response. TLR2 agonists from M. tuberculosis were found to suppress 
dendritic cell activation, type I interferon induction and antigen processing and presentation31, 32. The fine tuning 
of the inflammatory response, in particular through TLR2 signaling, is thought to be a strategy developed by 
the tuberculosis bacillus to achieve the various steps of its infectious cycle, from survival of the initial encounter 
with the host, to persistence in granulomas and finally to the induction of the central necrosis and rupture of 
the granuloma favoring bacterial release in the airways and transmission33. Perturbation of this fine tuning may 
be deleterious to the pathogen through increased production of toxic compounds, but also to the host through 
uncontrolled inflammation34, 35.
A surprising observation from this study was that several phenotypes associated with the Δpmt mutation 
are also found for the ΔlprG mutant, including the defect in colony formation on solid media and a similar level 
of attenuation in hMDM. However, our analyses with the strain producing LprG T231A, which is no longer 
glycosylable by Pmt, strongly argues against a direct role of LprG glycosylation in the corresponding pheno-
type. It is possible that the activity of a protein acting in the same pathway as LprG is strongly influenced by 
O-mannosylation. An obvious candidate is the efflux pump encoded by the gene Rv1410c in M. tuberculosis 
H37Rv. This gene forms an operon together with lprG and most of the phenotypes described for the ΔlprG 
mutant were only complemented upon expression of both Rv1410c and lprG (this study21, 22). We examined our 
mass spectrometry data in depth but found no evidence that the Rv1410c-encoded protein is O-mannosylated 
(data not shown). The impact of glycosylation on LprG activity thus remains an open question.
Another unexpected result from this study was the increased LAM production in the Δpmt mutants. This 
finding is not restricted to M. tuberculosis H37Rv because we observed the same for the M. smegmatis Δpmt 
mutant. Most of the additional lypoglycans were found in the culture supernatant. As discussed before, this 
enhanced secretion has a major impact on the inflammatory response of the host cell but the molecular basis 
for such abnormal production and secretion remains unclear. None of the enzymes known to be involved in the 
LAM biosynthetic pathway were identified among the O-mannosylated proteins (data not shown). One possible 
explanation may reside in the mannose flux. Indeed, Pmt is thought to transfer mannose residues from the same 
decaprenyl-phospho-mannose donor used for the elongation of PIM during the formation of LM and LAM36. 
The lack of Pmt may increase the amount of decaprenyl-phospho-mannose donor available for these other path-
ways. Another possibility is that genes of the LAM biosynthesis pathways are upregulated in the Δpmt strains. 
This is still speculative and additional work would be required to establish this point. However, such side effect 
was previously observed in mycobacteria for other mutants. For example, mutations that abolish the synthesis or 
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transport of glycopeptidolipid in the opportunistic pathogen Mycobacterium abscessus enhance the production 
of lipoproteins which, through their TLR2 agonist activity, stimulate an inflammatory response during host cell 
infection37.
In conclusion, protein O-mannosylation appears to modulate the production and secretion of inflammatory 
molecules such as LAM, but the underlying molecular mechanism remains to be established. The exposure of 
these lypoglycans, which act as strong TLR2 ligands, especially when associated with the lipoprotein LprG leads 
to modulation of the innate immune response, providing a possible explanation for the strong attenuation of the 
Δpmt M. tuberculosis strain in cellular and animal infection models.
Materials and Methods
Bacterial growth conditions. M. smegmatis mc2155 wild-type (WT) and M. smegmatis derivatives were 
cultured in Luria Bertani (LB) broth containing 0.05% Tween-80 or LB agar at 37 °C. M. tuberculosis WT and 
M. tuberculosis mutants were grown at 37 °C in liquid Middlebrook 7H9 broth (Difco) containing ADC (Becton 
Dickinson) and supplemented with 0.05% Tween-80 or in solid Middlebrook 7H11 broth supplemented with 
OADC (ADC with 0.005% oleic acid) (Becton Dickinson). Albumin free culture conditions for the M. tuberculo-
sis strains were performed in 7H9 broth supplemented with dextrose (1 g/L) and catalase (1.5 mg/L). For analysis 
of LAM, bacteria were grown without Tween-80. When necessary, media were supplemented with Hygromycin 
(Hyg) and Kanamycin (Km) at 50 µg/ml and 40 µg/ml respectively. Liquid cultures were grown to logarithmic or 
stationary phases depending of the needs.
E. coli DH5α was used for cloning experiments. Strains were grown at 37 °C in LB broth or LB agar. When 
necessary, Hyg (100 µg/ml) and Km (40 µg/ml) were added for selection of the appropriate strains.
In order to characterize the growth rate of M. tuberculosis WT and M. tuberculosis mutants, growth curves 
were monitored in 50 mL of 7H9 ADC 0.05% Tween-80. M. tuberculosis strains were grown until log-phase and 
then inoculated at 106 cfu/mL. OD 600 nm was measured at different time points for one month. The capacity of 
the different mutants to grow on solid media was evaluated on 7H11 OADC. M. tuberculosis cultures were grown 
until exponential phase, OD was measured and bacterial concentration was adjusted to 106 cfu/mL. Then, 10 μL 
of serial dilutions were plated. Morphology and size of spots were evaluated at 2–4 weeks of growth.
Every experiment involving WT or recombinant M. tuberculosis strains were performed in BSL3 laboratories 
until the samples were inactivated. Experiments with E. coli or M. smegmatis were realized in BSL1 laboratories.
Construction of M. smegmatis and M. tuberculosis mutants and complementation. M. tubercu-
losis knockout (KO) strains were constructed by homologous recombination using the recombineering system38. 
First, the allelic exchange substrate (AES) for each gene of interest: Rv0175c, Rv0315, Rv0838, Rv1411c and Rv3491 
were produced. Primers were designed with restriction sites to amplify upstream and downstream regions of 
the targeted genes (Supplementary Table S1) and PCR fragments were ligated to a Km resistance cassette. Then, 
M. tuberculosis H37Rv carrying a pJV53 derivative containing the hyg resistance gene was grown to mid-log 
phase, induced with acetamide and competent cells were prepared. This strain was transformed with each AES. 
Km-resistant colonies were obtained and replacement of the targeted gene by the AES was verified by PCR 
analysis (Supplementary Figure S1, Supplementary Table S1). As a result, M. tuberculosis ΔRv0175, ΔRv0315, 
ΔRv0838 (ΔlpqR), ΔRv1411c (ΔlprG) and ΔRv3491 mutants were obtained.
M. tuberculosis ΔlprG was complemented with Rv1410c, the lprG gene (Rv1411c) or both genes. Briefly, PCR 
products were amplified from M. tuberculosis H37Rv total DNA using primers indicated in Table S1 and inserted 
between PvuII and HindIII restriction sites of the integrative plasmid pMV361H39. In this construct, the gene 
expression is under the control of its own promoter.
M. tuberculosis H37Rv, ΔlprG and Δpmt gfp strains were made by insertion of the pMV361H GFP integrative 
plasmid. The various complemented strains expressing GFP were made using pMV361H GFP integrative plasmid 
carrying the PCR fragment of interest inserted between PvuII and HindIII sites (Supplementary Table S2).
Int e g r a t i v e  p l a s m i d  p M V 3 6 1 H  Rv 1 4 1 0 c - l p r G  A 6 9 1 G  g f p  w a s  c o n s t r u c t e d  u s i n g 
t he  pMV361H Rv1410c- lprG g fp  a s  template .  Br ie f ly,  t he  w hole  p lasmid  was  ampl i -
f i e d  u s i n g  C G A G A A G G T C C A G G T C G C G A A G C C C C C G G T G A G C T G A T C  a n d 
GATCAGCTCACCGGGGGCTTCGCGACCTGGACCTTCTCG primers. Then, the PCR product was trans-
formed in M. tuberculosis ΔlprG to obtain M. tuberculosis ΔlprG:: Rv1410c-lprG A691G gfp strain.
M. smegmatis_5447::res-Ωkm-res was complemented with pWM158 integrative plasmid which contains the 
Rv1002c gene from M. tuberculosis13.
Mouse Infections and qPCR analysis. Female BALB/c mice (7–8 week old) were purchased from the 
Centre d’Elevage Janvier and housed in the Institut de Pharmacologie et de Biologie Structurale ASB3 animal 
facilities. The M. tuberculosis WT and mutant strains were grown independently in standard liquid medium 
and an inoculum was prepared by mixing similar quantity of each clones. Mice, five per group, were infected 
intranasally with 40 μL PBS containing 6 × 102 cfu of the mixed population. At 1, 14 and 28 days post-infection, 
5 mice were euthanized and lungs and spleens were homogenized in 5 mL of PBS 0.05% Tween-80. The course of 
the global infection was followed by plating serial dilutions of 100 μL of lung and spleen homogenates on 7H11 
OADC solid medium. The remains of organ homogenates were centifugated at 800 rpm to remove clumps. The 
supernatants were then centifugated at 14000 rpm and bacilli were resuspended in 5 mL of 7H9 ADC Km. After 
one week of culture, mycobacterial DNA were extracted using DNeasy Blood and tissue extraction kit (Qiagen) 
according to the recommendations of the manufacturer.
Quantitative PCR analysis was performed in 25 μL reactions using the suitable set of primers (Supplementary 
Table S3), 5 μL of DNA as template and the maxima syber green qPCR master mix (thermo scientific). Reactions 
were performed on the Applied Biosystems 7500. The amplification program for qPCR was: 10 min at 95 °C, 
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followed by 40 cycles each consisting of 95 °C for 15 sec, 60 °C for 30 sec and 72 °C for 30 sec. Two PCR reactions 
were used for each mutant. The expression of the common part was used as internal control (qKmFint and qKm-
Rint primers). Specific values were first normalized with the common region and relative quantification was then 
calculated.
Cell Culture and infections. Human monocyte-derived macrophages (hMDMs) were prepared as pre-
viously described40. Briefly, human blood samples, obtained from the Etablissement Français du Sang of 
Toulouse (France), were collected from anonymous nontuberculous donors. Peripheral blood monocytes were 
cultured to differentiation for 7 days on glass coverslips in 24-well tissue culture plates (5.105 cells/well) con-
taining RPMI 1640 (Gibco, Cergy Pontoise, France) supplemented with 2 mM glutamine (Gibco) and 7% of 
heat-inactivated human AB serum. Before infections, hMDMs were washed twice with fresh RPMI medium. 
Bone marrow-derived macrophages from C57Bl6 (WT), TLR2 −/−, or MyD88−/− mice were differentiated 
in DMEM (Invitrogen) supplemented with 10% FCS (Fisher Scientific), 20% Macrophage Colony Stimulating 
Factor (M-CSF from L929 cell supernatant) and 10 mM HEPES (Invitrogen). The day before stimulation with 
LprG/LAM complex, macrophages were seeded into 96-well plates at a density of 5.104 cells/well.
Mycobacterial infections using hMDMs were performed as previously described40. Briefly, macrophages were 
infected with exponentially growing GFP-expressing mycobacteria at MOI 1 :1 in RPMI medium. Infection was 
allowed to proceed at 37 °C in 5% CO2 for 1 h, and the extracellular bacteria were removed by three successive 
washes with 1 mL fresh medium. At the end of the infection period, the cells were collected at 0, 3 and 7 days 
post-infection and fixed for 1 h at RT with 4% PFA in PBS supplemented with 15 mM sucrose, aldehyde groups 
were neutralized with 50 mM NH4Cl. Extracellular mycobacteria were labelled with rabbit anti-mycobacteria Ab, 
which was detected by a Rhodamine Red-conjugated goat anti-rabbit secondary Ab. Preparations were visualized 
under a Leica DMLA fluorescence microscope to count and calculate (i) the number of bacteria per macrophages 
and (ii) the number of macrophages containing at least one particle (percent internalization or phagocytosis). 
Data are expressed as relative values, calculated as the percentage of internalization or phagocytosis divided by 
control values. For each set of conditions, triplicate experiments were performed and at least 50 cells per slide 
were counted.
Quantification of NF-κB activity and cytokine secretion (TNF-α and IL-10). The level of NF-κB 
activation was studied using HEK-BlueTM hTLR2 reporter cell lines (InvivoGen). This cell line is stably trans-
fected with a reporter plasmid expressing a secreted embryonic alkaline phosphatase (SEAP) gene under the 
control of a NF-κB-dependent promoter. In all cases, cells were used in 96-well plates according to manufacturer 
instructions. Cells were treated with the purified proteins at the specified concentrations. Unstimulated cells 
were used as negative controls, whereas Pam3CSk4 10 ng/ml was used as positive control. After 16 h of incuba-
tion, QUANTI-BlueTM detection medium (InvivoGen) was used following manufacturer specifications and SEAP 
activity, corresponding to NF-κB activation, was determined by reading the absorbance at 630 nm. For infection 
experiments, HEK-BlueTM hTLR2 cells were infected with corresponding M. tuberculosis strains in 96-well plates 
at MOI 1:1 for 24 h. At the tested infection time, supernatants were harvested, filtered, and NF-κB activity was 
subsequently evaluated as described before.
To assess TNF-α or IL-10 secretion levels, THP-1 or MHS cells were infected at MOI 1:1 for 1 h and cytokines 
were evaluated after 5 h and 24 h for TNF-α and 24 and 48 h for IL-10. Cytokine secretions were quantified in 
supernatants of the THP-1 or MHS cells using the BD OptEIATM human TNF ELISA Set and BD OptEIATM 
human IL-10 ELISA set or the PeproTech murine TNF-α and IL-10 ABTS ELISA development kits respectively, 
according to the recommendations of the manufacturer. For BMDM, cells were incubated for 24 h with 100 ng/
ml LprG/LAM complexes purified from bacterial cells or culture medium of M. smegmatis Δpmt or M. smegma-
tis Δpmt complemented with pmt from M. tuberculosis. Unstimulated cells were used as negative controls (PBS 
1X), whereas Pam3CSK4 (100 ng/ml) and LPS (100 ng/ml) was used as positive control. TNF-α secretion was 
quantified in supernatants of the BMDM using the mouse TNF-α ELISA Set kit (eBioscience), according to the 
recommendations of the manufacturer. Data are expressed as picograms of cytokine per milliter of supernatant.
Cloning, expression and purification of His-tagged proteins. Cloning,  expres-
sion and purification of LprG and LprG T231A His-tagged proteins were performed as previ-
ously described with minor modification23. The lprG gene was amplified from M. tuberculosis H37Rv 
reference strain by PCR using the 5′-TTTTTTCATATGCGGACCCCCAGACGCCACTG-3′ and 
5′-TTTTTTACTAGTGCTCACCGGGGGCTTCG-3′ primers. The lprG A691G (lprG*) was amplified from the 
complementation plasmid using the same primers (underlined the NdeI and SpeI restriction enzyme sites). Both 
DNA fragments were inserted between the NdeI and SpeI sites of pWM218 mycobacterial replicative plasmid13 to 
obtain pLprG-His and pLprG T231A-His plasmids. The lprG gene expression is under the control of the pBlaF* 
promoter.
LprG and LprG T231A were expressed either in M. tuberculosis or in M. smegmatis. Cultures were centrifuged 
and pellet and medium were separated. Supernatants were filtered twice and concentrated to 2 mL by ultrafiltra-
tion with Vivaspin 10 kDa system (Sartorius). Cells were resuspended in 2 mL of PBS 1x pH 7.4 and disrupted. 
Insoluble material was removed from the lysate by centrifugation at 12000 rpm for 10 min at 4 °C and supernatant 
was incubated directly with Ni2+ beads (Qiagen) for 2–4 h at 4 °C in continuous agitation. The mix was trans-
ferred to polypropylene columns, washed with 5 volumes of wash buffer (PBS, 20 mM imidazole, pH7.4), and 
bound proteins were dissociated with aliquots of 100 μl of elution buffer (PBS, Imidazole from 100 to 500 mM). 
After purification, proteins were dialyzed 3 times in PBS pH 7.4. Protein purity was verified by SDS-PAGE with 
blue-Coomassie stain and Western-blot using anti-His antibody.
www.nature.com/scientificreports/
1 2SCIeNTIFIC REPORts | 7: 7913  | DOI:10.1038/s41598-017-08489-7
LAM detection in crude extracts. M. tuberculosis H37Rv, Δpmt, ΔlprG, ΔlprG:: lprG-Rv1410c and 
ΔlprG:: lprG* -Rv1410c were grown in 7H9 supplemented with ADC during one month. Cultures were cen-
trifuged and pellets and medium were separated. Supernatants were filtered and concentrated to 2 mL by ultra-
filtration with Vivaspin 10 kDa system (Sartorius). Bacterial pellets were resuspended in 2 mL of PBS 1x pH7.4 
and disrupted. Insoluble material was removed from the lysate by centrifugation at 12000 rpm for 10 min at 4 °C. 
The total amount of LAM was analyzed by Western blot using the CS-35 anti-LAM antibody. Anti-hsp65 or 
anti-Ag85A antibodies were used as controls.
Western blot analysis. Western blot analysis was carried out using standard procedures. Equivalent quan-
tities of protein extracts or purified proteins were separated by electrophoresis through a 4–20% precast protein 
gel (BioRad). Proteins were transferred to PVDF membranes for 50–60 min. After 1 h blocking with 5% milk in 
PBS supplemented with 0.05% Tween-20 (PBST), proteins were analyzed using specific antibodies: mouse mon-
oclonal anti-LAM (CS-35, BEI Resources, 1:50, overnight at 4 °C), mouse monoclonal anti-His6 (Affymetrix, 
1:3000, overnight at 4 °C), mouse monoclonal anti-Ag85 (Santa Cruz Biotechnology, 1 :1000, overnight at 4 °C), 
rabbit polyclonal anti-Hsp65 (gift from M. Daffé, 1:2000000, overnight at 4 °C) goat anti-mouse (BioRad, 1 :5000, 
1 h RT) or goat anti-rabbit (Sigma-Aldrich, 1:20000, 1 h RT) secondary antibodies conjugated with horseradish 
peroxidase (HRP).
Surface LAM staining. Ten days cultures were centrifuged at 800 rpm for 10 min to remove clumps. Bacilli 
were washed with PBS and fixed in 4% PFA. After centrifugation, pellets were washed with PBS and incubated at 
RT in 5% BSA for 1 h. Bacilli were sedimented and suspended in 3% BSA with mouse anti-LAM CS-35 at 1/150 
and incubated overnight at 4 °C. Bacilli were washed with PBS-0.05% Tween-20 and resuspended in PBS with 
goat anti-mouse IgG CMA-Rho red at 1/1000 for 2 h at RT. Bacilli were washed and analyzed by flow-cytometry. 
Relative quantification of LAM was calculated using H37Rv as reference level.
High-Resolution Mass Spectrometry. LC-ESI-MS and MS² analyses of intact recombinant LprG-His 
and LprG-His T231A were performed on a nanoRS UHPLC system (Dionex) coupled to an ETD-enabled 
LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher Scientific), with fluoranthene as reagent anion. 5 µL of 
sample was loaded on a C4-precolumn (300 µm ID × 5 mm, Thermo Fisher Scientific) at 20 µL/min in 5% ace-
tonitrile, 0.05% TFA. After 5 min desalting, the precolumn was switched online with the analytical C4 nanocol-
umn (75 µm ID × 15 cm, in-house packed with C4 Reprosil) equilibrated in 95% solvent A (5% acetonitrile, 0.2% 
formic acid) and 5% solvent B (0.2% formic acid in acetonitrile). Proteins were eluted using the following gradient 
of solvent B at 300 nL/min flow rate: 5 to 40% during 5 min; 40 to 100% during 33 min. The LTQ-Orbitrap Velos 
was operated either in single MS or in data-dependent acquisition mode with the XCalibur software. MS scans 
were acquired in the 500–2000 m/z range with the resolution set to a value of 60,000. For top-down experiments, 
survey scan MS were acquired in the same way, with a resolution at 30,000. Precursor ions were selected from an 
inclusion list established thanks to previous MS analyses and were fragmented in ETD and the resulting fragment 
ions were analyzed in the Orbitrap, at a resolution of 60,000. Isolation width was set at 5 m/z and activation time 
was fixed to 20 ms for ETD.
Ethics Statement. Animal studies were performed in accordance with the CNRS guidelines for housing 
and care of laboratory animals in compliance with the European Community council directive 86/609/EEC 
guidelines and its implementation in France. The procedures involving mice were reviewed and approved by the 
relevant Ethics Committee (Comité d’éthique en experimentation animale N°01) and received approval from 
the French Ministry for High Education and Research after ethical evaluation (number 201508271122464 v2 
(APAFIS#1535)). The Etablissement Français du Sang (Toulouse, France) provided human peripheral blood 
samples under contract 21/PLER/TOU/IPBS01/2013-0042. Experiments with human blood were performed 
in accordance with the relevant French guidelines and regulations (articles L1243-3, L1243-4 and L1245-2 of 
the French Public Health Code) and protocols were approved by the French Ministry for High Education and 
Research (agreement number DC 2012-1715). Informed consents were obtained from the donors before sample 
collection.
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